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ABSTRACT 
Innovations in transdermal drug delivery systems (TDDS) is an important influence to medical practice by providing advances i n the delivery of 
treatment with existing conventional drugs and novel drugs. Transdermal drug delivery is one of the most promising methods for drug 
application. It has several benefits over conventional system to offer sustained drug release, avoidance of first pass effect, patient compliance, 
ease of application and removal in case of toxicity as well as decrease in the side effects as compared with conventional therapy. Transdermal 
patches are dosage forms which transport drug to viable epidermal and dermal tissues of the skin for local therapeutic effect  while a very major 
fraction of drug is transported into the systemic blood circulation. Skin penetration enhancement techniques have been developed to improve 
bioavailability and increase the range of drugs for which topical and transdermal delivery. The purpose of this review is to introduce 
transdermal patches including type of transdermal patches, components of transdermal patches, method of preparation of TDDS, evaluation 
parameters, researches and development done on TDDS in last decade etc.   
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1. INTRODUCTION 
The conventional oral drug delivery systems are associated 
with numerous difficulties such as pass metabolism, 
fluctuation in plasma level, drug degradation in 
gastrointestinal tract due to enzymes, pH etc. These 
difficulties are overcome by introduction of novel drug 
delivery systems one of them is transdermal drug delivery 
systems. The most common transdermal system available in 
the market is called patches [Sachan et. al. 2013]. A 
transdermal patch is a medicated adhesive patch that is 
placed on the skin to deliver a specific dose of medication 
through the skin and into the bloodstream. It (Skin patch) 
uses a special membrane to control the rate at which the 
liquid drug contained in the reservoir within the patch can 
pass through the skin and into the bloodstream [Patel et. al. 
2012]. The main objective behind transdermal drug delivery 
system is to deliver drugs into systemic circulation through 
skin at predetermined rate with minimal inter and 
intrapatient variation. [Jalwal et. al. 2010] 
The basic components of any transdermal delivery system 
include the drug(s) dissolved or dispersed in a reservoir or 
inert polymer matrix; an outer backing film of paper, plastic, 
or foil, and a pressure-sensitive adhesive that anchors the 
patch to the skin. The adhesive is covered by a release liner 
which needs to be peeled off before applying the patch to the 
skin. Drugs administered via skin patches include 
scopolamine, nicotine, estrogen, nitroglycerin, and lidocaine. 
Transdermal delivery not only provides controlled, constant 
administration of the drug, but also allows continuous input 
of drugs with short biological half-lives, and eliminates 
pulsed entry into systemic circulation which often causes 
undesirable side effects [Gaikwad et. al. 2013]. 
1.1 IDEAL PROPERTIES OF TDDS 
The ideal properties of transdermal drug delivery system are 
as follows 
1. They have optimum partition coefficient required for the 
therapeutic action of drug. 
2. They have Shelf life up to 2 years. 
3. They have Low melting point of the drug is desired which 
is less than 200oC. 
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4. Patch size should be < 40cm2  
5. The pH of the saturated solution should be between 5 to 9 
[Chauhan et. al. 2015]. 
ADVANTAGES OF TDDS 
 Avoid first pass metabolism and gastro intestinal 
incompatibility. 
 Predictable and extended duration of action and 
Minimizes undesirable side effects. 
 Provides utilization of drugs with short biological half-
lives and narrow therapeutic window. 
 Improves physiological and pharmacological response. 
 Avoids the fluctuation in drug levels and Inter and intra 
patient variations. 
 Maintain plasma concentration of potent drugs.  
 Termination of therapy is easy at any point of time. 
 Provides greater patient compliance due to elimination 
of multiple dosing profiles. 
 Ability to deliver drug more selectively to a specific 
site.   
 Provide suitability for self-administration [Jalwal et. al. 
2010]. 
DISADVANTAGES OF TDDS 
 Some patients develop contact dermatitis at the site of 
application from one or more of the system components, 
necessitating discontinuation.  
 Only potent drugs are suitable candidates for 
transdermal patch because of the natural limits of drug 
entry imposed by the skin's impermeability. 
 Some drugs e.g. scopolamine transdermal patch placed 
behind the ear, it is uncomfortable [Mali et. al. 2015]. 
1.2 TRANSDERMAL PATCHES AND CONDITION OF 
USAGE 
Transdermal patch is used when the patient has intolerable 
side effects (including constipation) and who is unable to 
take oral medication (dysphagia) and is requesting an 
alternative method of drug delivery. It is used where the pain 
control might be improved by reliable administration. This 
might be useful in patients with cognitive impairment or 
those who for other reasons are not able to self-medicate 
with their analgesia. It can be used in combination with other 
enhancement strategies to produce synergistic effects [Patel 
et. al. 2012]. 
1.3 ROUTES OF DRUG PENETRATION THROUGH 
SKIN 
The diffusants has two potential entry routes to the blood 
vasculature; through the epidermis itself or diffusion 
through shunt pathway, mainly hair follicles with their 
associated sebaceous glands and the sweat ducts. Henceforth 
there are two major routes of penetration  
1.3.1 Transcorneal Penetration 
a) Intracellular penetration: Drug molecule passes 
through the cells of the stratum corneum. It is generally 
seen in case of hydrophilic drugs. As stratum corneum 
hydrates, water accumulates near the outer surface of 
the protein filaments. Polar molecules appear to pass 
through this immobilized water.  
b) Intercellular penetration: Non-polar substances 
follow the route of intercellular penetration. These 
molecules dissolve in and diffuse through the non- 
aqueous lipid matrix imbibed between the protein 
filaments.  
1.3.2 Trans-appendegeal Penetration 
It is also known as the shunt pathway. In this route, the drug 
molecule may transverse through the hair follicles, the 
sebaceous pathway of the pilosebacious apparatus or the 
aqueous pathway of the salty sweat glands. The 
transappendegeal pathway is considered to be of minor 
importance because of its relatively smaller area (less than 
0.1% of total surface). However, this route may be of some 
importance for large polar compounds [Gaikwad et. al. 
2013]. 
1.4 BASIC COMPONENTS OF TRANSDERMAL DRUG 
DELIVERY SYSTEMS 
Various components of a transdermal drug delivery system A 
transdermal therapeutic system is essentially a 
multilaminate structure that is composed of following 
constituents: 
1.4.1 Drug Substance 
For successfully developing a transdermal drug delivery 
system, the drug should be chosen with great care. The 
following are some of the desirable properties of a drug for 
transdermal delivery 
a. Physiochemical Properties: The drug should have a 
molecular weight less than 1000 Daltons, should have 
affinity for both lipophilic and hydrophilic phases and have a 
low melting point.  
b. Biological Properties: The drug should be potent with a 
daily dose of the order of a few mg/day, half-life (t½) should 
be short, must not produce allergic response and Tolerance 
must not develop under the near zero-order release profile 
of transdermal patches [Mali et. al. 2015]. 
 
Table 1 Ideal Properties of Drug for Transdermal Drug Delivery  
[Tanwar et. al. 2016] 
S. No. Parameters  Properties 
1.  Dose Less than 20mg/day 
2.  Half life                                                                                                                 < 10 hrs
3.  Molecular weight                                                                                                 <400 Daltons            
4.  Melting point                                                                                                           <200°C                                      
5.  Partition coefficient                                                                                                   1 to 4                       
6.  Aqueous solubility                                                                                                    >1mg/mL
7.  pH of the aqueous saturated solution                                                                         5-9  
8.  Skin Permeability Coefficient                                                                                 >0.5×10-3 cm/h  
9.  Skin Reaction                                                                               Non irritating and non-sensitizing  
10.  Oral Bioavailability                                                                                                Low  
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1.4.2 Polymer Matrix 
The polymer controls the release of the drug from the device 
following criteria should be satisfied for a polymer to be 
used in transdermal patches are Molecular weight, chemical 
functionality of the polymer should be such that the specific 
drug diffuses properly and gets released through it. The 
polymer should be stable, nontoxic, easily manufactured, 
inexpensive and its degradation product must be non toxic 
or non-antagonistic to the host.  
Types of Polymer: 
a) Natural polymers: Cellulose derivative, Gelatin, 
Waxes, Proteins, Gum, Shellac, Natural rubber, starch.  
b) Synthetic Elastomers: Hydrin rubber, silicone rubber, 
Nitrile, Acrylonitrile, Neoprene.  
c) Synthetic polymers: Polyvinyl alcohol, polyvinyl 
chloride, polyethylene, polypropylene, polyamide, 
polyurea, epoxy [Mali et. al. 2015]. 
1.4.3 Permeation Enhancers   
These are the compounds, which promote skin permeability 
by altering the skin as a barrier to the flux of a desired 
penetrant and are considered as an integral part of most 
transdermal formulations. Mainly to achieve and maintain 
therapeutic concentration of drug in the blood, the 
resistance of skin to diffusion of drugs has to be reduced in 
order to allow drug molecules to cross skin and to maintain 
therapeutic levels in blood. They can modify the skin’s 
barrier to penetration either by interacting with the 
formulation that applied or with the skin itself [Jalwal et. al. 
2010].
 
Table 2 Types of Absorption Enhancers [Tanwar et. al. 2016] 
S. No. Class Examples 
1.  Surfactants Na-lauryl sulfate  
Polyoxyethylene-9-laurylether, 
Bile salts, Na-deoxycholate 
2.  Fatty acids                                          Oleic acid,  Short fatty acids  
3.  Cyclodextrins    a-, b- and g cyclodextrins,    
Methylated b cyclodextrins 
4.  Chelating agents                                EDTA, Polyacrylates 
5.  Positively charged polymer            Chitosan salts, Trimethyl chitosan 
 
1.4.4 Drug Reservoir Components 
It must be compatible with the drug and must allow for drug 
transport at the desired rate. It must possess the desired 
adhesive and cohesive properties to hold the system 
together. Materials used are: mineral oils, Polyisobutylene, 
and colloidal silica, HPC. 
1.4.5 Backing Laminates 
The primary function of the backing laminate is to offer 
support, should be able to prevent drug from leaving the 
dosage form through top, impermeable to drugs and 
permeation enhancers. should a low moisture vapor 
transmission rate. They must have optimal elasticity, 
flexibility, and tensile strength. They must be chemically 
compatible with the drug, enhancer, adhesive and other 
excipients, relatively inexpensive and must allow printing 
and adhesive lamination. The backing membranes are 
composed of a pigmented layer, an aluminum vapor coated 
layer, a plastic film (polyethylene, polyvinyl chloride, 
polyester) and a heat seal layer. 
1.4.6 Rate Controlling Membrane: 
Rate controlling membranes in transdermal devices govern 
drug release from the dosage form. Membranes made from 
natural polymeric material such as chitosan show great 
promise for use as rate controlling membranes.  
1.4.7 Adhesive 
Pressure sensitive adhesive is a material that helps to 
adhere transdermal devices to the skin over long periods of 
time. These adhesives can be placed on the face of device 
known as face adhesive system (or) peripherally at the back 
of device known as peripheral adhesive system [Sirisha et. 
al. 2018]. 
The adhesive layer should not be irritant, leave an un 
washable residue on the skin and should be easily 
removable, have excellent contact with the skin, Physical & 
chemical compatibility with the drug. It should not be effect 
permeation of drug [Mali et. al. 2015]. 
The three major classes adhesive for potential applications 
in TDDS includes Polyisobutylene type pressure sensitive 
adhesives, Acrylic type pressure sensitive adhesives and 
Silicone type pressure sensitive adhesives 
1.4.8 Release Liners: 
The release liner has to be removed before the application of 
transdermal system, and it prevents the loss of the drug that 
has migrated into the adhesive layer during storage. It also 
helps to prevent contamination. It is composed of a base 
layer, which may be non-occlusive or occlusive, and a release 
coating layer made of silicon or Teflon. Other materials 
include polyesters, foil, Mylar and metallized laminates 
[Jalwal et. al. 2010]. 
1.5 TYPES OF TRANSDERMAL PATCH 
1.5.1 Adhesive Dispersion Type System 
The system consists of drug-impermeable backing 
membrane, the drug reservoir which is prepared by directly 
dispersing the drug in an adhesive polymer and then 
spreading the medicated adhesive by solvent casting or hot 
melting onto a flat sheet of drug-impermeable backing to 
form a thin drug reservoir layer. On top of this, a layer of 
rate-controlling adhesive polymer (non-medicated) of 
constant thickness is spread to produce an adhesive 
diffusion-controlled drug delivery system with detachable 
release liner which in an ideal situation is removed and the 
patch is applied to the skin for a required period of time. 
(Sachan) Illustration of this type of system is exampled by 
development and marketing of transdermal therapeutic 
system of angina pectoris and Valsartan as angiotensin II 
type 1 selective blocker for one-day medication 
a) Single-Layer Drug-In-Adhesive 
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The adhesive layer of this system also contains the drug. In 
this type of patch, the adhesive layer not only serves to 
adhere the various layers together, along with the entire 
system to the skin, but is also responsible for the releasing of 
the drug. The adhesive layer is surrounded by a temporary 
liner and a backing. 
b) Multi-Layer Drug-In-Adhesive  
The multi-layer drug in adhesive patch is similar to the 
single-layer system in that both adhesive layers are also 
responsible for the releasing of the drug. The multi-layer 
system is different however that it adds another layer of 
drug-in adhesive, usually separated by a membrane (but not 
in all cases). This patch also has a temporary liner-layer and 
a permanent backing [Mali et. al. 2015]. 
 
Fig. No. 1 Single layer in adhesive 
 
Fig. No. 2 Multi-layer in adhesive 
1.5.2 Membrane Permeation Controlled System 
In this system the drug reservoir is totally embedded in a 
compartment molded between a drug-impermeable backing 
laminate and a rate controlling polymeric membrane The 
drug molecules are permitted to release across the rate 
controlling membrane simply by diffusion process through 
the pores. In the reservoir compartments the drug solids are 
dispersed homogenously in a solid polymeric matrix (e.g. 
Polyisobutylene) suspended in the unleachable viscous 
liquid medium (e.g. silicon fluid) to form a gel-like 
suspension, or dissolved in a releasable solvent (e.g. alkyl 
alcohol) to form a gel like in solution. In this type of system 
the rate of release is zero order.  
 
Fig. No. 3 Membrane permeation controlled system 
(Reservoir system) 
 
 
1.5.3 Matrix 
The Matrix system has a drug layer of a semisolid matrix 
containing a drug solution or suspension. The adhesive layer 
in this patch surrounds the drug layer partially overlaying it. 
These type of patches are also known as monolithic device 
[Tanwar et. al. 2016]. 
Types of Matrix 
a) Drug-In-Adhesive System 
In this type the drug reservoir is formed by dispersing the 
drug in an adhesive polymer and then spreading the 
medicated adhesive polymer by solvent casting or melting 
on an impervious backing layer. On top of the reservoir, 
unmediated adhesive polymer layers are applied for 
protection purpose. 
b) Matrix-Dispersion System 
In this type the drug is dispersed homogenously in a 
hydrophilic or lipophilic polymer matrix. This drug 
containing polymer disk is fixed on to an occlusive base plate 
in a compartment fabricated from a drug impermeable 
backing layer. Instead of applying the adhesive on the face of 
the drug reservoir, it is spread along with the circumference 
to form a strip of adhesive rim.  
 
FIG. NO. 4 Matrix Drug Delivery System 
1.5.4 Microreservoir System:  
In this type the drug delivery system is a combination of 
reservoir and matrix-dispersion system. The drug reservoir 
is formed by first suspending the drug in an aqueous 
solution of water soluble polymer and then dispersing the 
solution homogeneously in a lipophilic polymer to form 
thousands of unreachable, microscopic spheres of drug 
reservoirs. This thermodynamically unstable dispersion is 
stabilized quickly by immediately cross-linking the polymer 
in situ by using cross linking agents.  
1.5.5 Vapour Patch 
In this type of patch, the role of adhesive layer not only 
serves to adhere the various layers together but also serves 
market, commonly used for releasing of essential oils in 
decongestion. Various other types of vapor patches are also 
available in the market which are used to improve the 
quality of sleep and reduces the cigarette smoking 
conditions [Chauhan et. al. 2015]. 
1.6 METHODS OF PREPARATION OF TRANSDERMAL 
PATCH 
[KADAM ET. AL. 201] [TANWAR ET. AL. 2016] [CHAUHAN 
ET. AL. 2015] 
a) Asymmetric TPX membrane method  
b) Circular Teflon mould method  
c) Mercury substrate method  
d) By using “IPM membranes” method  
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e) By using “EVAC membranes” method 
f) Preparation of TDDS by using Proliposomes 
g) By using free film method 
a) Asymmetric TPX membrane method: A prototype 
patch can be fabricated by a heat sealable polyester lm 
(type 1009, 3m) with a concave of 1cm diameter used 
as the backing membrane. Drug sample is dispensed 
into the concave membrane, covered by a TPX {poly (4-
methyl-1-pentene)} asymmetric membrane, and sealed 
by an adhesive. These are prepared by using the 
dry/wet inversion process. TPX is dissolved in a 
mixture of solvent (cyclohexane) and nonsolvent 
additives at 60°c to form a polymer solution. The 
polymer solution is kept at 40°C for 24 hrs and cast on 
a glass plate. Then casting film is evaporated at 50°C 
for 30 secs, then the glass plate is to be immersed 
immediately in coagulation bath [maintained the 
temperature at 25°C]. After 10 minutes of immersion, 
the membrane can be removed, air dry in a circulation 
oven at 50°C for 12 hrs]. 
b) Circular Teflon Mould Method: Solutions containing 
polymers in various ratios are used in an organic 
solvent. Calculated amount of drug is dissolved in half 
the quantity of same organic solvent. Plasticizer added 
into drug polymer solution. The total contents are to be 
stirred and then poured into a circular Teflon mould. 
And rate of solvent vaporization controlled with 
placing inverted glass funnel on Teflon mould. The 
solvent is allowed to evaporate for 24 hrs. The dried 
films are to be stored in desiccators. 
c) Mercury substrate method: In the polymeric solution 
drug &plasticizer get dissolved. It is kept for 10-15min 
stirring to produce homogenous dispersion then it is 
poured into leveled mercury surface, covered with 
inverted funnel to control solvent evaporation. 
d) By Using IPM Membranes Method: In this method 
drug is dispersed in a mixture of water and propylene 
glycol containing carbomer 940 polymers and stirred 
for 12 hrs in magnetic stirrer. The dispersion is to be 
neutralized and made viscous by the addition of 
triethanolamine. Buffer pH 7.4 can be used in order to 
obtain solution gel, if the drug solubility in aqueous 
solution is very poor. The formed gel will be 
incorporated in the IPM membrane. 
e) By using “EVAC membranes” method: In order to 
prepare the target transdermal therapeutic system, 1% 
carbopol reservoir gel, polyethelene (PE), ethylene 
vinyl acetate copolymer (EVAC) membranes can be 
used as rate control membranes. If the drug is not 
soluble in water, propylene glycol is used for the 
preparation of gel. Drug is dissolved in propylene 
glycol, carbopol resin will be added to the above 
solution and neutralized by using 5% w/w sodium 
hydroxide solution. The drug (in gel form) is placed on 
a sheet of backing layer covering the specied area. A 
rate controlling membrane will be placed over the gel 
and the edges will be sealed by heat to obtain a leak 
proof device 
f) Preparation of TDDS by using Proliposomes: By 
carrier method using film deposition technique 
Proliposomes are prepared. Drug and lecithin ratio 
should be 0.1:2.0 taken as an optimized one from 
previous references. For the preparation of 
Proliposomes in 100ml round bottom flask take 5mg of 
mannitol powder, then it is kept at 60-70°c 
temperature and the flask is rotated at 80-90 rpm and 
dried the mannitol at vacuum for 30 minutes. After 
drying, the temperature of the water bath is adjusted 
to 20- 30°C. Drug and lecithin are dissolved in a 
suitable organic solvent mixture, a 0.5ml aliquot of the 
organic solution is introduced into the round bottomed 
flask at 37°C, after complete drying second aliquots 
(0.5ml) of the solution is to be added. After the last 
loading, the flask containing Proliposomes are 
connected in a lyophilizer and subsequently drug 
loaded mannitol powders (Proliposomes) are placed in 
a desiccator overnight and then sieved through 100 
mesh. The collected powder is transferred into a glass 
bottle and stored at the freeze temperature until 
characterization. 
g) By using free film method: Free film of cellulose 
acetate is prepared by casting on mercury surface. A 
polymer solution 2% w/w is prepared by using 
chloroform. Plasticizers are incorporated at a 
concentration of 40% w/w of polymer weight. Five ml 
of polymer solution was poured in a glass ring which is 
placed over the mercury surface in a glass petri dish. 
The rate of evaporation of the solvent is controlled by 
placing an inverted funnel over the petridish. The lm 
formation is noted by observing the mercury surface 
after complete evaporation of the solvent. The dry lm 
will be separated out and stored between the sheets of 
wax paper in desiccators until use. Free films of 
different thickness can be prepared by changing the 
volume of the polymer solution 
1.7 EVALUATION METHODS:  
[Gaikwad et. al. 2013] [Tanwar et. al. 2016] [Chauhan et. al. 
2015] [Kadam et. al. 201] [Sachan et. al. 2013]  
a) Physicochemical Evaluation: Interaction studies the 
drug and the excipients must be compatible with one 
another to produce a product that is stable. The 
interaction between drug and excipients affect the 
bioavailability and stability of the drug. If the 
excipients are new and have not been used in 
formulations containing the active substance, the 
compatibility studies play an important role in 
formulation development. Interaction studies are 
taken out by Thermal analysis, Fourier transform 
infrared spectroscopy (FTIR), ultra violet (UV) and 
chromatographic techniques by comparing their 
physicochemical properties like assay, melting point, 
wave numbers, and absorption maxima 
b) Thickness of the patch: At different points the 
thickness of the patch is measured by using digital 
mirometer& determine average thickness & standard 
deviation of the same.  
c) Weight of uniformity: Before testing the patch is 
dried at 60 c for 4 hrs. Cut that patch in different parts 
& weighed in digital balance. Take average weight & 
calculate standard deviation from individual weight. 
d) Folding endurance: A specific area of strip is cut and 
repeatedly folded at the same place till it broke. The 
number of times the film could be folded without 
breaking gave the value of folding endurance.  
e) Percentage moisture content: The prepared patches 
are to be weighed individually and to be kept in a 
desiccator containing fused calcium chloride at room 
temperature. After 24 h, the films are to be reweighed 
and the percentage moisture content determined by 
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below formula: Percentage moisture content (%) = 
[Initial weight - Final weight / Final weight] ×100 
f) Percentage moisture uptake: The prepared patches 
are to be weighed individually and to be kept in a 
desiccator containing saturated solution of potassium 
chloride in order to maintain 84% Rhesus factor (RH). 
After 24 h, the films are to be reweighed and the 
percentage moisture uptake determined by the 
formula  
Percentage moisture uptake (%) = (Final weight - 
Initial weight / initial weight) × 100 
g) Moisture Uptake: Weighed films are kept in a 
desiccator at room temperature for 24 h. These are 
then taken out and exposed to 84% relative humidity 
using saturated solution of Potassium chloride in a 
desiccator until a constant weight is achieved. % 
moisture uptake is calculated as given below. 
 % moisture uptake = Final weight – Initial weight X 
100 
h) Determination of surface pH: Specific number of 
patches are kept in contact with distilled water and 
excess water is drained and pH noted by pH meter. 
i) Peel adhesion test:Here peel adhesion is the force 
required to remove an adhesive coating from a 
substrate. A single tape is applied to a stainless steel 
plate then tape is pulled from the substrate at a 180° 
angle, and the required to pull the tape is measured. 
j) Thumb tack test:This test determines the tack 
property of adhesive .Thumb is pressed on adhesive & 
tack property is determined.  
k) Flatness test: Three longitudinal strips are cut from 
different portions of the films. The length of the each 
stripis measured and the variation in length because of 
non-uniformity in flatness is measured bydetermining 
percentage constriction, with 0% constriction 
equivalent to 100% flatness  
l) Percentage elongation break test: Percentage 
elongation can be determined by using following 
formula: 
                    Elongation percentage = L1-L2*100/L2 
Where L1 is the final length of each strip & L2 is the 
initial length of each strip. 
m) Rolling ball tack test: This test determines the 
softness of the polymer that relates the talk. Here the 
stainless steel ball of size 7/16 inches in diameter is 
released on an inclined track so that it rolls down & 
comes in contact with horizontal, upward facing 
adhesive .Distance travelled by ball along adhesive 
track gives the measurement of tack expressed in inch. 
n) Quick stick (Peel-tack) test: The Peel force required 
to break the bond between on adhesive and substrate 
is measured by pulling the force away from the 
substrate at 90o at a speed of 12inch/min. 
o) Probe tack test:Here the probe with specific surface 
kept in contact with adhesive so as to form bond 
between them. Then probe is remove so that it 
mechanically break it.The force required to pull the 
probe is the tack measured in terms of grams 
p) Flatness:A transdermal patch should possess a smooth 
surface and should not constrict with time. This can be 
demonstrated with flatness study. For flatness 
determination, one strip is cut from the centre and two 
from each side of patches. The length of each strip is 
measured and variation in length is measured by 
determining percent constriction. Zero percent 
constriction is equivalent to 100 percent flatness. 
% constriction = I1 – I2 X 100 
I2 = Final length of each strip 
I1 = Initial length of each strip 
q) Folding Endurance: Evaluation of folding endurance 
involves determining the folding capacity of the films 
subjected to frequent extreme conditions of folding. 
Folding endurance is determined by repeatedly folding 
the film at the same place until it break. The number of 
times the films could be folded at the same place 
without breaking is folding endurance value 
r) Tensile Strength:To determine tensile strength, 
polymeric films are sandwiched separately by corked 
linear iron plates. One end of the films is kept fixed 
with the help of an iron screen and other end is 
connected to a freely movable thread over a pulley. The 
weights are added gradually to the pan attached with 
the hanging end of the thread. A pointer on the thread 
is used to measure the elongation of the film. The 
weight just sufficient to break the film is noted. 
s) Shear strength properties: Shear strength is the 
measurement of the cohesive strength of an adhesive 
polymer. Adequate cohesive strength of a device will 
mean that the device will not slip on application and 
will leave no residue on removal. It is determined by 
measuring the time it takes to pull on adhesive coated 
tape off a stainless steel plate when a specified weight 
is hung from the tape which pulls the tape in a 
direction parallel to the plate. 
t) Drug content: Take the patch with specific area 
dissolve it in specific volume of solvent. Solution is 
then filtered and the drug content analyzed with the 
suitable method (UV or HPLC technique).Then take the 
average of three different samples.  
u) Uniformity of dosage unit test:Take ten patches and 
content determined for individual patches. If 9 out of 
10 patches have content between 85 to 115% of the 
specified value and one has content not less than 75 to 
125% of the specified value, then transdermal patches 
pass the test of content uniformity. But if 3 patches 
have content in the range of 75 to 125%, then 
additional 20 patches are tested for drug content. If 
these 20 patches have range from 85 to 115%, then the 
transdermal patches pass the test 
v) Polariscope examination: The instrument 
polariscope used to study the crystal structure of drug 
in a patch. A specifiec area of patch is cut and kept on 
the slide to observe that drug present in crystalline 
form or amorphous form. 
w) Stability studies: Stability studies were conducted 
according to the International Conference on 
Harmonization (ICH) guidelines by storing the TDDS 
samples at 40 ± 0.5°C and 75 ± 5% RH for 6 months. 
The samples were withdrawn at 0, 30, 60, 90 and 180 
days and analyzed suitably for the drug content. 
x) Skin irritation test:This study is performed on 
healthy rabbits (average weight 1.2-1.5kg). Remove 
the dorsal surface of rabbit by shaving & clean by using 
spirit. Formulation applied on skin surface & remove 
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after 24hrs & skin is to be observed & classified in to 5 
grades on the basis of severity of skin injury. 
y) In-vitro permeation studies K-C cell (Keshary –chein) 
diffusion cell is used if skin of rats are used. Hairless 
skin is used and skin is thoroughly cleaned of any 
adhering tissues or blood vessels and equilibrated for 
an hour in pH 7 buffer before running for experiment. 
The K.C. cell or skin piece was mounted between the 
compartment of the diffusion cell and donor 
compartment and epidermal part of skin upward or 
toward donor compartment. The patch to be tested 
was placed on skin. Specific butter media at 370 C + 10 
C is used as receptor phase and stirred with magnetic 
stirrer. Specific amount of sample withdrawn at 
regular period through the sampling port and fresh 
receptor fluid was added. Absorbance of sample is 
measured spectrophotometrically at against blank. The 
cumulative amount of drug permeated is ploted against 
time in hours. 
z) In-vitro drug release studies  A modified dissolution 
apparatus consisting of a jacketed vertical glass beaker 
18cm long and 48cm in diameter was used for 
assessment of the release of drug from patches. The 
specific amount of formulation of buffer solution. The 
patch to be evaluated is struck on to the depression 
(15mm internal diameter and 1.5mm depth) on a 
teflon block fabricated for the purpose and is put into 
the glass beaker containing the dissolution medium. 
The apparatus was equilibrated to 37 + 20 C and 
operated at 50 rpm. Specific amount of sample pipette 
out of reguler interval of time. Sample are filtered out 
through filter paper and finally membrane filtered the 
sample is analyzed by the HPLC or U.V. 
spectrophotometer. 
aa) In-Vivo methods: In-vivo evaluation of trandermal 
patch can be carried out using – i) Animal models ii) 
Human Volunteers Animal models In Vivo animals 
models are preferred because considerable time and 
resources are required to carry out studies in humans. 
Some of the species are used : mouse, rat, guinea pig, 
rabbit, rat, cat, dog, pig, house, monkey small hairy 
animals (e.g. rat, rabbit) or rhesus monkey is most 
reliable or in vivo evaluation of transdermal patches 
standard radiotracer methodology used. The 
application site is generally the abdomen which are the 
least hairy site on the animals body. The compound is 
applied after light clipper showing of the site. 
1.8. RESEARCH UNDERTAKEN ON LAST DECADE 
Kriplani Priyanka, et. al. (2018), formulated transdermal 
films of non-steroidal anti-inflammatory drug Diclofenac 
sodium using mercury substrate method and evaluated for 
physicochemical parameters like thickness, weight variation, 
moisture uptake, moisture content, folding endurance, and 
drug content values. Three transdermal patches were 
prepared using different concentrations of ethyl cellulose by 
solvent casting method. They concluded that as the 
concentration of polymer increases the thickness of patch, 
weight uniformity and folding endurance increases, 
percentage moisture content and percentage moisture 
uptake decreases with increase in polymer concentration. 
Asha et. al. (2017), developed a transdermal patch of 
Indomethacin using patchouli oil as a natural enhancer to 
increase transdermal permeation of the drug from the 
matrix system across rat epidermis.The transdermal flux 
obtained of the different concentration of patchouli oil tend 
to increase with increasing concentration of the oil and the 
maximum transdermal flux of 61.92 ± 0.89 μg/cm2/hr was 
obtained with formulation F7 (containing 1% w/v of 
patchouli oil). They concluded that a potential enhancing 
effect of patchouli oil on the transdermal permeation of the 
model drug Indomethacin and may be used as natural 
permeation enhancer in transdermal drug delivery systems. 
Bhagyeshwar G., et. al. (2017), prepared and evaluated 
transdermal drug delivery (TDDS) of Metformin 
Hydrochloride (MFH) using combinations of polyvinyl 
pyrrolidone K30 and Hydroxypropylmethylcellulose E50 in 
different ratios by solvent evaporation technique. Polyvinyl 
alcohol was used to prepare the backing membrane and 
dibutyl phthalate as plasticizer. They concluded that 
Metformin hydrochloride that released from the 
transdermal patches of F7 (PVP K30- HPMC E50 2.5:1) are 
best suited for once a day drug delivery. 
Ahmed Tarek A. et. al. (2016), developed an ethosomal 
formulation of Glimepiride then formulated transdermal 
films to offer lower drug side effect, extended release 
behavior and avoid first pass effect. Four formulation factors 
were optimized for their effects on vesicle size (Y1), 
entrapment efficiency (Y2) and vesicle flexibility (Y3). The 
optimized ethosomal formulation showed observed values 
for Y1, Y2 and Y3 of 61 nm, 97.12% and 54.03, respectively. 
Ethosomal formulation could be considered a suitable drug 
delivery system especially when loaded into transdermal 
vehicle with possible reduction in side effects and 
controlling the drug release. 
Vishvesh B Kanabar, et. al. (2015), prepared transdermal 
patches of Cefdinir using various polymers such as Cellulose 
derivatives, polyvinyl alcohol, Polyethylene, Polypropylene, 
Polyvinylpyrrolidone and Polymethyl methacrylate with 
their different concentration by the solvent evaporation 
technique by using PEG-400 as plasticizer. They concluded 
that among various polymers HPMC K100M was found to be 
the best polymer used to prepare transdermal patches. 
Ahmed Tarek A.et. al. (2014), developed Rabeprazole 
(RP)-alginate core coated chitosan nanoparticles (NP) 
utilizing water-in-oil (W/O) nanoemulsion technique and 
formulated transdermal patches loaded with RP-NP that 
avoid drug per-oral acid sensitivity and first pass effect. 
Chitosan, oil phase and surfactant to oil ratios had significant 
effects on Y1, while Y2 was significantly affected by the same 
variables affecting Y1 and span80-tween80 ratio. Patches 
loaded RP-NP exhibited substantial skin permeability and 
controlled drug release, and were in favor of Fickian 
diffusion. 
Zhao Lili et. al. (2014), prepared and evaluated a 
Ropivacaine-loaded microemulsion (ME) formulation and 
microemulsion-based carbopol gel (ME-gel) for transdermal 
delivery. The optimal ME formulation was comprised of 15 
% Capryol 90, 53 % Smix and 32 % water, respectively. The 
results of ex vivo permeation study showed that Ropivacaine 
had a significant higher cumulative amount from ME than 
that from ME-gel. ME and ME-gel presented a remarkable 
analgesic activity on acetic acid-induced writhing in mice. 
They concluded that ME could be a promising formulation 
for Ropivacaine transdermal administration. 
Madan Jyotsana R., et. al. (2014), formulated transdermal 
patches of Donepezil for improving patient compliance, 
therapeutic efficacy and to reduce the frequency of dosing 
and side effects and to avoid its extensive first pass 
metabolism. The system containing Eudragit S -100, 
Eudragit E -100 and HPMC as matrix forming agent and 
glycerin as plasticizer was the best formulation. Tween-80 
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(0.83 % w/w) was found to be the best among all 
penetration enhancers. 
Yang Zhen et. al. (2013), designed and evaluated a 
reservoir-type transdermal delivery system (TDS) of Bufalin 
for various formulation variables like different penetration 
enhancers, formulation matrix, rate controlling membranes 
as well as biopharmaceutical characteristics. Transdermal 
drug delivery of Bufalin provide sustained release rate and 
avoids the peak concentration, which prolong the duration 
of action and decrease the risk of side effect. They 
demonstrated that transdermal administration can deliver 
adequate Bufalin across skin on rodent models. Both in vitro 
and in vivo studies showed consistent results that with 
optimized chemical enhancer and formulation components, 
Bufalin can achieve sustained and sufficient delivery across 
skin. 
Sun Lin,et. al. (2012), formulated adhesive transdermal 
patch containing Azasetron andevaluated the correlation 
between in vitro and in vivo release. The effects of different 
adhesives, permeation enhancers, and loadings of Azasetron 
used in patches on the penetration of Azasetron through 
rabbit skin were investigated using two-chamber diffusion 
cells in vitro. For in vivo studies, Azasetron pharmacokinetic 
parameters in Bama miniature pigs were determined 
according to a noncompartment model method after topical 
application of transdermal patches and intravenous 
administration of Azasetron injections. The best permeation 
profile was obtained with the formulation containing DURO-
TAK 87-9301 as adhesive, 5% of isopropylmyristate as 
penetration enhancer, and 5% of Azasetron. The permeation 
profiles through porcine skin in vitro and in vivo suggested 
that Azasetron could effectively penetrate through the skin 
and pass into the systemic circulation. 
Maheshwari Rahul G.S.et. al. (2012), formulated, 
evaluated and compared the transdermal potential of novel 
vesicular nanocarriers; ethosomes and ultradeformable 
liposomes, containing clotrimazole(CLT), an anti-fungal 
drug. The ethosomal formulation (ET4) and ultradeformable 
liposomal(UL) formulation (TT3) showed highest 
entrapment 68.73±1.4% and 55.51±1.7%, 
optimalnanometric size range 132±9.5 nm and 121±9.7 nm, 
and smallest polydispersity index0.027±0.011 and 
0.067±0.009, respectively. Their results suggested that 
ethosomes to be the most proficient carrier system for 
dermal and transdermal delivery of clotrimazole. 
Patel Kunal N. et. al. (2011), formulated adhesive 
transdermal patches of diclofenac acid using Pressure 
Sensitive Adhesive (PSA) like acrylic adhesive by the solvent 
evaporation technique. Different concentrations of Labrasol, 
oleic acid and triacetin were used to enhance the 
transdermal permeation of diclofenac acid. 12 formulations 
were formulated. All prepared formulations indicated good 
physical stability. In vitro skin permeation studies of 
formulations were performed by using Franz diffusion cells. 
Formulation F3 containing 5% drug, 85% adhesive solution 
and 10% triacetin as permeation enhancer showed best in 
vitro skin permeation through human cadaver skin as 
compared to all other formulations. 
PrajapatiShailesh T.,et. al. (2011), formulated and 
evaluated of transdermal patch of Repaglinideto sustain the 
release and improve bioavailability of drug and patient 
compliance. Nine formulations were prepared by varying the 
grades of HPMC and concentration of PVP K30 by solvent 
casting method. The prepared formulations were evaluated 
for various parameters like thickness, tensile strength, 
folding endurance, % elongation, % moisture content, % 
moisture uptake, % drug content, in vitro drug release, in 
vitro permeation, and drug excipient compatibility. Batch F6 
was considered optimum batch which contained HPMC 
K100 and PVP (1.5%), showed release 92.343% up to 12 hr, 
and was more similar to the theoretical predicted 
dissolution profile ( f2 = 69.187). 
Shah Samip S., et. al.  (2010), formulated and evaluated 
transdermal patches of Papaverine hydrochloride by solvent 
casting method using ethyl cellulose:PVP, PVA:PVP, and 
Eudragit RL-100:Eudragit RS-100 in different ratios. The 
formulation containing PVA: PVP as polymers showed faster 
release rate (hydrophilic polymers) compared to Eudragit 
RL-100: Eudragit RS-100 (hydrophobic polymers) or 
combination of hydrophilic and hydrophobic polymers 
(ethyl cellulose and PVP). The formulated patches containing 
the hydroplilic polymers showed best release rate of drug. 
Jamakandi V.G. et. al. (2009), formulated and evaluated 
matrix-type transdermal patches of Nicorandilan 
antihypertensive drugusing different polymeric grades of 
hydroxy propyl methyl cellulose (6cps, 15cps, and 
K4M).They evaluated matrix-type patches for their 
physicochemical characterization followed by in vitro 
evaluation. Among the six different HPMCformulations they 
had formulated, transdermal patch with 6 cps and 6% 
w/vDMSO as permeation enhancer showed maximum 
releaseand offered least resistance to the movement of the 
drugmolecule due to its high hydrophilic nature and high 
waterpermeability value to water. 
Murthy etal, 2008 studied the Influence of polymers on the 
release of Carvediol from transdermal films and revelated 
many interested and important factors related to release 
rate of the drug due to polymers. 
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